Búsqueda | Portal de Búsqueda de la BVS España

1.

Tumor Necrosis Factor-α Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.

Manilall, Ashmeetha; Mokotedi, Lebogang; Gunter, Sulè; Le Roux, Regina; Fourie, Serena; Flanagan, Colleen A; Millen, Aletta M E.

J Cardiovasc Pharmacol; 81(6): 411-422, 2023 06 01.

Artículo en Inglés | MEDLINE | ID: mdl-37078863

2.

Increased protein phosphatase 5 expression in inflammation-induced left ventricular dysfunction in rats.

Manilall, Ashmeetha; Mokotedi, Lebogang; Gunter, Sulè; Le Roux, Regina; Fourie, Serena; Flanagan, Colleen A; Millen, Aletta M E.

BMC Cardiovasc Disord; 22(1): 539, 2022 12 09.

Artículo en Inglés | MEDLINE | ID: mdl-36494772

3.

Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome.

Maione, Luigi; Fèvre, Anne; Nettore, Immacolata Cristina; Manilall, Ashmeetha; Francou, Bruno; Trabado, Séverine; Bouligand, Jérôme; Guiochon-Mantel, Anne; Delemer, Brigitte; Flanagan, Colleen A; Macchia, Paolo Emidio; Millar, Robert P; Young, Jacques.

Hum Reprod; 34(1): 137-147, 2019 Jan 01.

Artículo en Inglés | MEDLINE | ID: mdl-30476149

4.

Inflammation-induced left ventricular fibrosis is partially mediated by tumor necrosis factor-α.

Manilall, Ashmeetha; Mokotedi, Lebogang; Gunter, Sulè; Le Roux, Regina; Fourie, Serena; Flanagan, Colleen A; Millen, Aletta M E.

Physiol Rep; 9(21): e15062, 2021 11.

Artículo en Inglés | MEDLINE | ID: mdl-34713972

5.

A crucial role for Galphaq/11, but not Galphai/o or Galphas, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition.

White, Colin D; Coetsee, Marla; Morgan, Kevin; Flanagan, Colleen A; Millar, Robert P; Lu, Zhi-Liang.

Mol Endocrinol; 22(11): 2520-30, 2008 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-18801931

6.

Glu^2.53(90) of the GnRH receptor is part of the conserved G protein-coupled receptor structure and does not form a salt-bridge with Lys^3.32(121).

Manilall, Ashmeetha; Stander, B Andre; Madziva, Michael T; Millar, Robert P; Flanagan, Colleen A.

Mol Cell Endocrinol; 481: 53-61, 2019 02 05.

Artículo en Inglés | MEDLINE | ID: mdl-30476558

7.

Identification of Tyr(290(6.58)) of the human gonadotropin-releasing hormone (GnRH) receptor as a contact residue for both GnRH I and GnRH II: importance for high-affinity binding and receptor activation.

Coetsee, Marla; Millar, Robert P; Flanagan, Colleen A; Lu, Zhi-Liang.

Biochemistry; 47(39): 10305-13, 2008 Sep 30.

Artículo en Inglés | MEDLINE | ID: mdl-18771291

8.

Gonadotropin-releasing hormone receptors.

Millar, Robert P; Lu, Zhi-Liang; Pawson, Adam J; Flanagan, Colleen A; Morgan, Kevin; Maudsley, Stuart R.

Endocr Rev; 25(2): 235-75, 2004 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-15082521

9.

Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor.

Mamputha, Sipho; Lu, Zhi-Liang; Roeske, Roger W; Millar, Robert P; Katz, Arieh A; Flanagan, Colleen A.

Mol Endocrinol; 21(1): 281-92, 2007 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-16973761

10.

Expression, structure, function, and evolution of gonadotropin-releasing hormone (GnRH) receptors GnRH-R1SHS and GnRH-R2PEY in the teleost, Astatotilapia burtoni.

Flanagan, Colleen A; Chen, Chun-Chun; Coetsee, Marla; Mamputha, Sipho; Whitlock, Kathleen E; Bredenkamp, Nicholas; Grosenick, Logan; Fernald, Russell D; Illing, Nicola.

Endocrinology; 148(10): 5060-71, 2007 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-17595228

11.

Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding.

Flanagan, Colleen A; Manilall, Ashmeetha.

Front Endocrinol (Lausanne); 8: 274, 2017.

Artículo en Inglés | MEDLINE | ID: mdl-29123501

12.

GPCR-radioligand binding assays.

Flanagan, Colleen A.

Methods Cell Biol; 132: 191-215, 2016.

Artículo en Inglés | MEDLINE | ID: mdl-26928545

13.

Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist.

Ott, Thomas R; Troskie, Brigitte E; Roeske, Roger W; Illing, Nicola; Flanagan, Colleen A; Millar, Robert P.

Mol Endocrinol; 16(5): 1079-88, 2002 May.

Artículo en Inglés | MEDLINE | ID: mdl-11981042

14.

The carboxy-terminal tail or the intracellular loop 3 is required for ß-arrestin-dependent internalization of a mammalian type II GnRH receptor.

Madziva, Michael T; Mkhize, Nonhlanhla N; Flanagan, Colleen A; Katz, Arieh A.

Mol Cell Endocrinol; 411: 187-97, 2015 Aug 15.

Artículo en Inglés | MEDLINE | ID: mdl-25957085

15.

Histidine(7.36(305)) in the conserved peptide receptor activation domain of the gonadotropin releasing hormone receptor couples peptide binding and receptor activation.

Mayevu, Nkateko M I; Choe, Han; Abagyan, Ruben; Seong, Jae Young; Millar, Robert P; Katz, Arieh A; Flanagan, Colleen A.

Mol Cell Endocrinol; 402: 95-106, 2015 Feb 15.

Artículo en Inglés | MEDLINE | ID: mdl-25583361

16.

Serine residues 338 and 339 in the carboxyl-terminal tail of the type II gonadotropin-releasing hormone receptor are critical for beta-arrestin-independent internalization.

Ronacher, Katharina; Matsiliza, Nosisa; Nkwanyana, Nonhlanhla; Pawson, Adam J; Adam, Tasneem; Flanagan, Colleen A; Millar, Robert P; Katz, Arieh A.

Endocrinology; 145(10): 4480-8, 2004 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-15205374

17.

Pro7.33(303) of the human GnRH receptor regulates selective binding of mammalian GnRH.

Fromme, Bernhard J; Katz, Arieh A; Millar, Robert P; Flanagan, Colleen A.

Mol Cell Endocrinol; 219(1-2): 47-59, 2004 Apr 30.

Artículo en Inglés | MEDLINE | ID: mdl-15149726

18.

Receptor conformation and constitutive activity in CCR5 chemokine receptor function and HIV infection.

Flanagan, Colleen A.

Adv Pharmacol; 70: 215-63, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-24931198

19.

Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.

de Voux, Alex; Chan, Mei-Chi; Folefoc, Asongna T; Madziva, Michael T; Flanagan, Colleen A.

PLoS One; 8(1): e54532, 2013.

Artículo en Inglés | MEDLINE | ID: mdl-23355876

20.

R31C GNRH1 mutation and congenital hypogonadotropic hypogonadism.

Maione, Luigi; Albarel, Frederique; Bouchard, Philippe; Gallant, Megan; Flanagan, Colleen A; Bobe, Regis; Cohen-Tannoudji, Joelle; Pivonello, Rosario; Colao, Annamaria; Brue, Thierry; Millar, Robert P; Lombes, Marc; Young, Jacques; Guiochon-Mantel, Anne; Bouligand, Jerome.

PLoS One; 8(7): e69616, 2013.

Artículo en Inglés | MEDLINE | ID: mdl-23936060

Portal de Búsqueda de la BVS España

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Tumor Necrosis Factor-α Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.

Increased protein phosphatase 5 expression in inflammation-induced left ventricular dysfunction in rats.

Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused by GNRHR mutations and women with polycystic ovary syndrome.

Inflammation-induced left ventricular fibrosis is partially mediated by tumor necrosis factor-α.

A crucial role for Galphaq/11, but not Galphai/o or Galphas, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition.

Glu^2.53(90) of the GnRH receptor is part of the conserved G protein-coupled receptor structure and does not form a salt-bridge with Lys^3.32(121).

Identification of Tyr(290(6.58)) of the human gonadotropin-releasing hormone (GnRH) receptor as a contact residue for both GnRH I and GnRH II: importance for high-affinity binding and receptor activation.

Gonadotropin-releasing hormone receptors.

Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor.

Expression, structure, function, and evolution of gonadotropin-releasing hormone (GnRH) receptors GnRH-R1SHS and GnRH-R2PEY in the teleost, Astatotilapia burtoni.

Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding.

GPCR-radioligand binding assays.

Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist.

The carboxy-terminal tail or the intracellular loop 3 is required for ß-arrestin-dependent internalization of a mammalian type II GnRH receptor.

Histidine(7.36(305)) in the conserved peptide receptor activation domain of the gonadotropin releasing hormone receptor couples peptide binding and receptor activation.

Serine residues 338 and 339 in the carboxyl-terminal tail of the type II gonadotropin-releasing hormone receptor are critical for beta-arrestin-independent internalization.

Pro7.33(303) of the human GnRH receptor regulates selective binding of mammalian GnRH.

Receptor conformation and constitutive activity in CCR5 chemokine receptor function and HIV infection.

Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.

R31C GNRH1 mutation and congenital hypogonadotropic hypogonadism.